Cancer And Leukemia Group B Memorandum

To:

Clinical Research Associates

From:

Debbie Sawyer, Director of Data Operations

Kathy Karas, Senior Protocol Editor

Subject:

New Malignancy and Long-Term Follow-up Reporting

Date:

October 15, 2004

Submission of new malignancies including new primaries (tumors not likely resulting from therapy for a previous cancer) <u>and</u> secondary malignancies (tumors resulting from treatment for a previous cancer including AML/MDS) should be reported on the CALGB: New Malignancy Form (C-1001v2, attached) and submitted to the Statistical Center. This form replaces the CALGB: Secondary AML/MDS form C-215. In addition to this form, continue to report:

- any diagnosis of AML/MDS following treatment for cancer on NCI-sponsored trials with investigational agents to the CALGB Central Office using the NCI/CTEP Secondary AML/MDS Report Form.
- all other secondary malignancies using the routine adverse event reporting mechanism outlined in the protocol.

Report long-term follow-up data on the updated CALGB Long-Term Follow-up Form (C-400v4, attached).

All open studies that use these forms (with the exception of 90104 and 90202) have been updated to reflect this change, which is effective October 15, 2004. The C-215 form has been retired.



CALGB: LONG-TERM

(Last name, First name)

FOLLOW-UP FORM				
CALGB Form		C	400	
CALGB Study No.			$\perp \parallel$	
CALGB Patient ID				
From: / [
To: (date last	/			
known alive or M M date of death)	ט כ	YYY	Y	
Are data amended?			Yes	
rticipating Group				
Participating Group Study No				
rticipating Group Patient ID				
w-up withdrawn (Consent wit	hdrawal s	tatement sig	gned	
ent's pnysician must be subm is no longer required once sig	ned state	ata Operatio ment is	oris.	
o ne nengan e quine				
ng this reporting period?	☐ No	☐ Yes		
YYY				
	☐ No	☐ Yes		
YYY				
	□No	☐ Yes		
	□No	□ Vos		
		☐ 1es		
	□No	☐ Yes		
orm.				
TING PERIOD				
col treatment during this repor	ting perio	d? □ No		
M	Y			
Date form /	\Box /		П	
	CALGB Form CALGB Study No. CALGB Patient ID From:	CALGB Form CALGB Study No. CALGB Patient ID From: To: (date last known alive or M M D D D date of death) Are data amended? Inticipating Group Inticipating Group Patient ID Inticipa	CALGB Form CALGB Study No. CALGB Patient ID From: To: (date last	

DD M M Stat Use Only

Page 1 of

Form: C-400 v4

Completed by: _

09/07/2004



CALGB: NEW MALIGNANCY FORM

INSTRUCTIONS: Complete and suby the protocol. Information in the completed for this form to be acceptuse black ink. Mark an X in the appropriate choice. Print text in capital letters edges of the boxes. If data are amend check the "Yes" box. If submitting your records. If submitting by fax, unaximum clarity in transmission and submitting electronically, click the Scompleted the form.	apper right box must be ted. For optimal accuracy ropriate box for fields with a . Avoid contact with the ended, circle amended items ng by mail, retain a copy for se an original form for d fax to 919-416-4990. If	CALGB Form CALGB Study No. CALGB Patient ID Diagnosis date of new malignancy Are data amended?	C-1001			
Patient Initials Last, First Mic	ldle	Participating Group				
Patient Hospital No.	Patient Hospital No		Participating Group Study No			
Institution/Affiliate		Participating Group Patient ID				
 A secondary malignancy related to cancer treatment, including AML/MDS Submit pathology and/or cytogenetic report(s) documenting the new primary or new secondary malignancy along with this form. DO NOT REPORT RECURRENCES ON THIS FORM. Record new malignancy type, site and histology below. 						
		ify site:	Specify histologic type:			
New primary New seco malignancy maligna						

Stat Use Only
Page 1 of 1

150/5